Literature DB >> 20660395

Revisiting the rosiglitazone story--lessons learned.

Clifford J Rosen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20660395     DOI： 10.1056/NEJMp1008233

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  39 in total

Review 1.  Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.

Authors:  M Angelyn Bethel; Harald Sourij
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

2.  Neutral Loss Scan - Based Strategy for Integrated Identification of Amorfrutin Derivatives, New Peroxisome Proliferator-Activated Receptor Gamma Agonists, from Amorpha Fruticosa by UPLC-QqQ-MS/MS and UPLC-Q-TOF-MS.

Authors:  Chu Chen; Ying Xue; Qing-Miao Li; Yan Wu; Jian Liang; Lin-Sen Qing
Journal:  J Am Soc Mass Spectrom       Date:  2018-02-05       Impact factor: 3.109

3.  Potential negative cardiovascular effects of calcium supplements.

Authors:  P Burckhardt
Journal:  Osteoporos Int       Date:  2011-03-16       Impact factor: 4.507

4.  Endpoint selection and relative (versus absolute) risk reporting in published medication trials.

Authors:  Michael Hochman; Danny McCormick
Journal:  J Gen Intern Med       Date:  2011-08-13       Impact factor: 5.128

5.  Drug safety meta-analysis: promises and pitfalls.

Authors:  Michael A Stoto
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

6.  Protein sets define disease states and predict in vivo effects of drug treatment.

Authors:  David Meierhofer; Christopher Weidner; Ludger Hartmann; Johannes A Mayr; Chung-Ting Han; Frank C Schroeder; Sascha Sauer
Journal:  Mol Cell Proteomics       Date:  2013-04-11       Impact factor: 5.911

7.  Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.

Authors:  Chieh-Hsiang Lu; Chen-Yi Yang; Chung-Yi Li; Cheng-Yang Hsieh; Huang-Tz Ou
Journal:  Diabetologia       Date:  2017-11-14       Impact factor: 10.122

8.  Inhibition of HDAC3 promotes ligand-independent PPARγ activation by protein acetylation.

Authors:  Xiaoting Jiang; Xin Ye; Wei Guo; Hongyun Lu; Zhanguo Gao
Journal:  J Mol Endocrinol       Date:  2014-06-30       Impact factor: 5.098

Review 9.  Nuclear receptors and epigenetic regulation: opportunities for nutritional targeting and disease prevention.

Authors:  Donato F Romagnolo; Janos Zempleni; Ornella I Selmin
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

10.  Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.

Authors:  Xavier Nadal; Carmen Del Río; Salvatore Casano; Belén Palomares; Carlos Ferreiro-Vera; Carmen Navarrete; Carolina Sánchez-Carnerero; Irene Cantarero; Maria Luz Bellido; Stefan Meyer; Gaetano Morello; Giovanni Appendino; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2017-11-02       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.